GlassScriptPhysician profile
Heather M Lake
NPI 1295857043
$13,280.41
in general payments reported to CMS, 2019-2025
22 companies · $2,633 in 2025
The $2,633 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $690 · 2021: $981 · 2022: $2,218 · 2023: $2,614 · 2024: $2,918 · 2025: $2,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,852 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,852.31 |
| Education | $311.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,882.16 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,619.05 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $1,359.62 | 2021-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $1,246.34 | 2021-2025 | Saphnelo |
| Amgen INC. | $997.33 | 2019-2025 | Evenity, Prolia, Enbrel |
| Novartis Pharmaceuticals Corporation | $801.92 | 2021-2025 | |
| Ucb, INC. | $554.59 | 2020-2025 | Bimzelx, Cimzia |
| Ani Pharmaceuticals, INC. | $508.53 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $386.97 | 2020-2025 | Tymlos |
| Lilly USA, LLC | $252.21 | 2022-2024 | Taltz |
| Almatica Pharma LLC | $161.04 | 2024-2025 | Teriparatide |
| Aurinia Pharma U.S., INC. | $123.32 | 2023 | |
| Pfizer INC. | $93.96 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $58.64 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $50.60 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $44.81 | 2023-2024 | Actemra |
| Sandoz INC. | $43.69 | 2024 | Hyrimoz |
| Horizon Therapeutics Plc | $27.40 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $18.20 | 2024 | Opsumit, Uptravi |
| Tonix Medicines, INC. | $18.06 | 2025 | Tonmya |
| Scilex Pharmaceuticals INC. | $17.86 | 2024 | |
| Mallinckrodt Enterprises LLC | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Lake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.